The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Tumour cells typically exhibit a G1 cell cycle arrest in response to the MEK1/2 [mitogen-activated protein kinase/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitor selumetinib, but do not die, and thus they acquire resistance. In the present study we examined the effect of combining selumetinib with the BH3 [BCL2 (B-cell lymphoma 2) homology domain 3]-mimetic BCL2 inhibitor ABT-263. Although either drug alone caused little tumour cell death, the two agents combined to cause substantial caspase-dependent cell death and inhibit long-term clonogenic survival of colorectal cancer and melanoma cell lines with BRAFV600E or RAS mutations. This cell death absolutely required BAX (BCL2-associated X protein) and was inhibited by RNAi (RNA interference)-mediated knockdown of BIM (BCL2-interacting mediator of cell death) in the BRAFV600E-positive COLO205 cell line. When colorectal cancer cell lines were treated with selumetinib plus ABT-263 we observed a striking reduction in the incidence of cells emerging with acquired resistance to selumetinib. Similar results were observed when we combined ABT-263 with the BRAFV600E-selective inhibitor PLX4720, but only in cells expressing BRAFV600E. Finally, cancer cells in which acquired resistance to selumetinib arises through BRAFV600E amplification remained sensitive to ABT-263, whereas selumetinib-resistant HCT116 cells (KRASG13D amplification) were cross-resistant to ABT-263. Thus the combination of a BCL2 inhibitor and an ERK1/2 pathway inhibitor is synthetic lethal in ERK1/2-addicted tumour cells, delays the onset of acquired resistance and in some cases overcomes acquired resistance to selumetinib.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ABT-263 in combination with selumetinib increased caspase-dependent cell death through Bax and effectively reduced the incidence of CRC-acquired resistance to selumetinib [40].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [40]
In the citing paper
“As a result, inhibition of ERK1/2 signalling in tumour cells invariably promotes the expression of pro-apoptotic BIM, BMF and/or PUMA11.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [11]
In the citing paper
“ERK1/2 signalling also represses BMF protein expression11,”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [11]
In the citing paper
“Indeed, ERK1/2 pathway inhibitors combine with navitoclax, or the close analogue ABT-737, to induce colorectal cancer (CRC) apoptosis and tumour regression in vivo11,25,26.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [11]
In the citing paper
“however, we and others have noted more limited synergy between ERK1/2 pathway inhibitors and navitoclax/ABT-737 in melanoma11,26–28.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [11]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,240
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185
BRAF Mutations in Hairy-Cell Leukemia
Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014209 · Cited by 1,024
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies
Kim, H., Rafiuddin-Shah, M., Tu, H.-C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1499 · Cited by 874
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633
Ley, R., Balmanno, K., Hadfield, K., Weston, C., & Cook, S. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301010200 · Cited by 608
Self-citationRudin, C. M., Hann, C. L., Garon, E. B., Ribeiro de Oliveira, M., Bonomi, P. D., Camidge, D. R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 564
The role of Bcl-2 family members in tumorigenesis
Kirkin, V., Joos, S., & Zörnig, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.009 · Cited by 548
Activation of the Protein Kinase ERK5/BMK1 by Receptor Tyrosine Kinases
Kamakura, S., Moriguchi, T., & Nishida, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26563 · Cited by 510
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484
Self-citationJoseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008990107 · Cited by 449
Elgendy, M., Sheridan, C., Brumatti, G., & Martin, S. J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.009 · Cited by 426
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Yecies, D., Carlson, N. E., Deng, J., & Letai, A. (2010) · Blood · doi:10.1182/blood-2009-07-233304 · Cited by 360
Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 210
Self-citationCragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207
Wang, Y. F., Jiang, C. C., Kiejda, K. A., Gillespie, S., Zhang, X. D., & Hersey, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0665 · Cited by 194
ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL
Ewings, K. E., Hadfield‐Moorhouse, K., Wiggins, C. M., Wickenden, J. A., Balmanno, K., Gilley, R., Degenhardt, K., White, E., & Cook, S. J. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601723 · Cited by 176
Self-citationWeston, C. R., Balmanno, K., Chalmers, C., Hadfield, K., Molton, S. A., Ley, R., Wagner, E. F., & Cook, S. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206261 · Cited by 176
Self-citationHikita, H., Takehara, T., Shimizu, S., Kodama, T., Shigekawa, M., Iwase, K., Hosui, A., Miyagi, T., Tatsumi, T., Ishida, H., et al. (2010) · Hepatology · doi:10.1002/hep.23836 · Cited by 150
Balmanno, K., Chell, S. D., Gillings, A. S., Hayat, S., & Cook, S. J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24604 · Cited by 143
Self-citationUpregulation of two BH3-only proteins, Bmf and Bim, during TGFβ-induced apoptosis
Ramjaun, A. R., Tomlinson, S., Eddaoudi, A., & Downward, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209852 · Cited by 131
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 119
Self-citationWang, C., & Youle, R. J. (2012) · Oncogene · doi:10.1038/onc.2011.497 · Cited by 113
Caja, L., Sancho, P., Bertrán, E., Iglesias‐Serret, D., Gil, J., & Fabregat, I. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1482 · Cited by 110
Gillings, A. S., Balmanno, K., Wiggins, C. M., Johnson, M. A., & Cook, S. J. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07329.x · Cited by 108
Self-citationERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest
Todd, D. E., Densham, R. M., Molton, S. A., Balmanno, K., Newson, C., Weston, C. R., Garner, A. P., Scott, L. A., & Cook, S. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207467 · Cited by 92
Self-citationSheridan, C., Brumatti, G., Elgendy, M., Brunet, M., & Martin, S. J. (2010) · Oncogene · doi:10.1038/onc.2010.380 · Cited by 71
Zhang, W., Konopleva, M., Burks, J. K., Dywer, K. C., Schober, W. D., Yang, J.-Y., McQueen, T. J., Hung, M.-C., & Andreeff, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0878 · Cited by 70
Wickenden, J. A., Jin, H., Johnson, M., Gillings, A. S., Newson, C., Austin, M., Chell, S. D., Balmanno, K., Pritchard, C. A., & Cook, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.335 · Cited by 67
Self-citationLopez, J., Hesling, C., Prudent, J., Popgeorgiev, N., Gadet, R., Mikaélian, I., Rimokh, R., Gillet, G., & Gonzalo, P. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.21 · Cited by 64
Kennedy, R., Kemp, T. J., Sugden, P. H., & Clerk, A. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.04.011 · Cited by 52
ARC Synergizes with ABT-737 to Induce Apoptosis in Human Cancer Cells
Bhat, U. G., Pandit, B., & Gartel, A. L. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0919 · Cited by 19
Cited by
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Self-citationTargeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401
Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling
Cook, S. J., Stuart, K., Gilley, R., & Sale, M. J. (2017) · The FEBS Journal · doi:10.1111/febs.14122 · Cited by 170
Self-citationERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 160
Self-citation
Metadata
- Authors
- Sale, M. J., & Cook, S. J.
- Affiliations
- Babraham Institute (GB)
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2013-02-15
- Volume
- 450
- Issue
- 2
- Pages
- 285-294
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2316080015
- Cited by
- 58
- References
- 50
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 9 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 11 · 2014: 8 · 2013: 5
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (C488/A14867, 14867)
- Biotechnology and Biological Sciences Research Council (BB/E02162X/1, BB/F0158521/1, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- navitoclax, selumetinib, BH3 mimetics, BCL-2 inhibitor, MEK inhibitors, acquired drug resistance, building information modeling, Bax, caspase-dependent cell death, synthetic lethality, BRAF V600E mutation, RAS mutations, colorectal cancer, melanoma, PLX4720, combination therapy
- MeSH terms
- Aniline Compounds, Benzimidazoles, Humans, Sulfonamides, Cell Death, Apoptosis, Drug Resistance, Neoplasm, HT29 Cells, MAP Kinase Signaling System, RNA Interference, Cell Line, Tumor, MAP Kinase Kinase 1, MAP Kinase Kinase 2, bcl-2-Associated X Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.